References
- Schon MP, Boehncke WH Psoriasis. N Engl J Med 2005;352:1899-912
- Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7
- Thomas VD, Yang FC, Kvedar JC Biologics in psoriasis: a quick reference guide. J Am Acad Dermatol 2005;53:346-51
- Griffiths CE, Barker JN Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-71
- Lebwohl M. Psoriasis. Lancet 2003;361:1197-204
- Sobell JM, Kalb RE, Weinberg JM Management of moderate to severe plaque psoriasis (part I): clinical update on antitumor necrosis factor agents. J Drugs Dermatol 2009;8:147-54
- Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003;4:441-7
- Christophers E, Griffiths CE, Gaitanis G, et al. The unmet treatment need for moderate to severe psoriasis: results of a survey and chart review. J Eur Acad Dermatol Venereol 2006;20:921-5
- Menter A, Griffiths CE Current and future management of psoriasis. Lancet 2007;370:272-84
- Naldi L, Griffiths CE Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005;152:597-615
- Ishak WHW, Siraj F. Artificial intelligence in medical applications: an exploration. Health Informatics Europe. Available at: http://www.hi-europe.info/files/2002/9980.htm [Last accessed 10 August 2009]
- Brodie MJ, Kwan P. The star systems: overview and use in determining antiepileptic drug choice. CNS Drugs 2001;15:1-12; discussion 3-5
- Ferrari MD, Goadsby PJ, Lipton RB, et al. The use of multiattribute decision models in evaluating triptan treatment options in migraine. J Neurol 2005;252:1026-32
- Zeleny M. Multiple Criteria Decision Making. New York: McGraw Hill, 1982
- European Medicines Agency (EMEA). Committee for Medicinal Products for Human Use. Summary of positive opinion for Stelara. London, 20 November 2008
- Trial watch: novel biologic for psoriasis shows superiority over current best-seller. Nat Rev Drug Discov 2008;7:880-1
- European Medicines Agency (EMEA). EMEA recommends suspension of the marketing authorisation of Raptiva (efalizumab). London, 19 February 2009
- Ortonne J-P, Griffiths CE, Daudén E, et al. Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study. Expert Rev Dermatol 2008;3:657-65
- Lipton RB, Cutrer FM, Goadsby PJ, et al. How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians. Curr Med Res Opin 2005;21:413-24